VIP
ImmuneVasoactive Intestinal Peptide — Synthetic Peptide
Overview
Vasoactive Intestinal Peptide (VIP) is an endogenous 28-amino acid neuropeptide belonging to the secretin/glucagon superfamily, produced throughout the central and peripheral nervous systems, immune cells, and gastrointestinal tract. It was initially characterized as a vasodilator and gastrointestinal motility regulator but has since been established as a pleiotropic signaling molecule with potent immunomodulatory, neuroprotective, and autonomic regulatory functions.
VIP signals through three G protein-coupled receptors: VPAC1 (expressed in brain, lung, liver, lymphocytes), VPAC2 (expressed in brain, pancreas, smooth muscle, mast cells), and PAC1 (primarily targeted by PACAP). The wide distribution of these receptors explains VIP's diverse physiological and pathological roles. VIP is an investigational agent with no FDA approval for any therapeutic use; its short plasma half-life (~1-2 minutes) and broad receptor distribution have historically limited clinical development.
Mechanism of Action
VIP exerts its anti-inflammatory effects primarily through VPAC1 receptor engagement in immune cells. Receptor activation stimulates adenylyl cyclase, raises intracellular cAMP, and activates protein kinase A, which inhibits NF-κB nuclear translocation — the master regulator of pro-inflammatory cytokine transcription. This results in suppressed production of TNF-α, IL-1β, IL-6, IL-12, and IL-17, while promoting IL-10 (anti-inflammatory) production. VIP simultaneously induces the generation of induced regulatory T cells (iTreg), suppressing autoimmune Th1 and Th17 responses.
In the nervous system, VIP acts as a neuroprotective neuromodulator. It reduces excitotoxicity, prevents neuronal apoptosis, supports microglial homeostasis, and modulates dopaminergic and cholinergic neurotransmission. Neuroprotective mechanisms involve both direct neuronal VPAC receptor signaling and indirect protection through suppression of neuroinflammatory glial activation.
In the gastrointestinal tract, VIP acts as an inhibitory neurotransmitter, relaxing smooth muscle, promoting secretion from intestinal crypts, and regulating gastrointestinal motility as part of the enteric nervous system.
Research Dosing
IV administration used in research settings for pulmonary hypertension and hemodynamic studies. Extremely short plasma half-life (~1-2 minutes) makes systemic IV dosing impractical for chronic indications. Not approved for any indication.
Intranasal delivery explored for respiratory and neurological conditions. VIP nasal spray is compounded by specialized pharmacies for clinical research use. Half-life extends to approximately 1-2 hours intranasally. No FDA approval.
Inhaled VIP studied in pulmonary arterial hypertension and respiratory conditions. Aerosolized delivery targets pulmonary VPAC receptors directly, reducing systemic effects from the short half-life.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.
Published Studies
Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease
Delgado M, Ganea D — Cellular and Molecular Immunology, 2009
Comprehensive review establishing VIP as a potent anti-inflammatory regulator of innate immunity, demonstrating its suppression of LPS-induced NF-κB translocation, inhibition of pro-inflammatory cytokine production (TNF-α, IL-6, IL-12), promotion of IL-10, and stimulation of regulatory T cell generation. Established VPAC1 as the primary immunomodulatory receptor.
PMID: 19604262 →ReviewTherapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders
White CM, Ji S, Cai H, Maudsley S, Martin B — CNS and Neurological Disorders Drug Targets, 2010
Reviewed VIP's neuroprotective and neuromodulatory roles, documenting its potential as a therapeutic target in Alzheimer's disease, Parkinson's disease, and autism spectrum disorders. Highlighted challenges of poor metabolic stability and limited CNS penetration as barriers to clinical development.
PMID: 20632962 →ReviewVasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases
Delgado M, Pozo D, Ganea D — Pharmacological Reviews, 2002
Foundational review demonstrating VIP's capacity to suppress autoimmune inflammatory cascades in animal models of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and Crohn's disease through Th1/Th17 inhibition and iTreg induction.
PMID: 11862320 →AnimalTherapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
Dror E, Dalmas E, Meier DT, et al. — Frontiers in Endocrinology, 2022
Demonstrated VIP/VPAC2 axis promotes pancreatic beta-cell proliferation through FoxM1 pathway activation, positioning VPAC2-selective agonists as potential therapeutic targets for type 2 diabetes by expanding functional beta-cell mass.
PMID: 36204104 →